Key Takeaways Sarepta Therapeutics (SRPT) announced that it has sold at least $174 million worth of its equity investment in Arrowhead Pharmaceuticals to help fund a milestone payment to the latter. Shares of Sarepta rose around 9% on Wednesday in response to the announcement. Year to date, the stock has plunged 83.2% compared with the industry's 2% decline. Image Source: Zacks Investment Research SRPT's Deal with Arrowhead SRPT Stock on Investors' Radar Sarepta has been facing a lot of heat from investors ...